Clinical Rheumatology

, Volume 7, Issue 1, pp 46–49 | Cite as

A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease

  • G. T. Sunderland
  • J. J. F. Belch
  • R. D. Sturrock
  • C. D. Forbes
  • A. J. McKay
Originals

Summary

The peripheral vasospastic symptoms associated with Raynaud's disease continue to be an unsolved clinical problem. Hexopal (Hexanicotinate inositol) has shown promise in uncontrolled studies and its use in patients with Raynaud's disease may reduce such vasospasm. This study examines the effects of 4 g/day of Hexopal or placebo, during cold weather, in 23 patients with primary Raynaud's disease. The Hexopal group felt subjectively better and had demonstrably shorter and fewer attacks of vasospasm during the trial period. Serum biochemistry and rheology was not significantly different between the two groups. Although the mechanism of action remains unclear Hexopal is safe and is effective in reducing the vasospasm of primary Raynaud's disease during the winter months.

Key words

Hexopal Controlled Trial Raynaud's Disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ring, E.F.J., Bacon, P.A. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena. J Intern Med Res 1977, 5, 217–222.CrossRefGoogle Scholar
  2. 2.
    Aylward, M. Hexopal in Raynaud's disease. J Intern Med Res 1979, 7, 484–491.Google Scholar
  3. 3.
    Holti, G. An experimentally-controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Intern Med Res 1979, 7, 473–483.Google Scholar
  4. 4.
    Belch, J.J.F., Drury J.K., Capell, H. et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1983, 313–315.Google Scholar
  5. 5.
    Acciari, L., Camevale, F., Della Selva, A. Thermography in the hand angiopathy from vibrating tools. Acta Therm 1976, 1, 18–28.Google Scholar
  6. 6.
    McLaren, M., Belch, J.J.F., Forbes, C.D., Prentice, C.R.M. Development of a radioimmunoassay for the measurement of prostacyclin metabolites in unextracted plasma. Thrombosis Research 1985, 37, 177–183.CrossRefPubMedGoogle Scholar
  7. 7.
    Granstrom, E., Kindahl, H., Samuelsson, B. Radioimmunoassay for Thromboxane β2. Analytical Letters 1976, 7, 611–627.CrossRefGoogle Scholar
  8. 8.
    Clauss, A. Gerinnungsphysioloische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957, 17, 237–251.CrossRefPubMedGoogle Scholar
  9. 9.
    Alkjaersig, N., Fletcher, A.P., Sherry, S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959, 38, 1086–1088.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kluft, C., Brakman, P., Veldhuyzen-Stalk, E.C., Screening of the fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis. Eds: Davidson, J.F., Samama, M.M., Desnoyers, P.C.: New York, Raven Press, 1976, Vol. 2, 57–62.Google Scholar

Copyright information

© Acta Medica Belgica 1988

Authors and Affiliations

  • G. T. Sunderland
    • 1
  • J. J. F. Belch
    • 2
  • R. D. Sturrock
    • 2
  • C. D. Forbes
    • 2
  • A. J. McKay
    • 3
  1. 1.University Department of SurgeryGlasgow Royal InfirmaryGlasgowScotland
  2. 2.University Department of MedicineGlasgow Royal InfirmaryGlasgowScotland
  3. 3.Department of SurgeryGartnavel General HospitalGlasgowScotland

Personalised recommendations